An Interview with Prof. Pruszczyk on Acute Pulmonary Embolism Clinical Consensus Statement
Watch now to hear Prof. Pruszczyk, one of the authors from the ESC working group address: why this topic is important to the working group, what are the key takeaways and the call for action in treatment of Acute PE
The RETHRO study presented at LINC 2022.
Watch now Prof. Kucher presenting the RETHRO study (2017-2021) where EKOS ultrasound accelerated thrombolysis has been used to treat patients with intermediate and high-risk Pulmonary Embolism at LINC 2022.
Catheter Lysis with EKOS in Pulmonary Embolism
Hear from Prof. Sharp while he shares case base presentation including clinical evidence to date for Pulmonary Embolism treatment using EKOS at LINC 2022.
The Zurich Pathway presented at LINC 2022
Hear from Prof. Nils Kucher share Zurich Pulmonary Embolism patient pathway for Intermediate-High Risk and High Risk patients, with a case base discussion. And some data showing the effect of ultrasound in-vitro.
EXPERT-PE Conference 2022
Boston Scientific hosted a symposium dedicated to Pulmonary Embolism during the EXPERT-PE Conference in Leiden on Saturday, October 15th. Our session on "EKOS Endovascular System: the most studied interventional PE device, what questions remain unanswered" was moderated by Prof. Erik Klok and other expert leaders such as Prof. Konstantinides and Prof. Sharp were highly involved in the discussion sharing their best practices around the treatment of PE.
Acute Pulmonary Embolism Consensus Statement by ESC & EAPCI
The paper, authored by a a team of PE expert leaders, serves as a practical guide for catheter directed therapies, confirming their clinical success, complementary to the formal guidelines when approaching the treatment of PE.
EKOS Pulmonary Embolism Forum 2022 Hong Kong
Boston Scientific is committed to helping practitioners to learn more about Pulmonary Embolism: how to diagnose it, how to treat it, and when it’s right to intervene.
Hear the expert Pr. Andrew Sharp discussing on the effectiveness of EKOS to reverse RV dysfunction and hemodynamic instability, and its association with low risk of bleeding and mortality in Intermediate to high-risk Pulmonary Embolism patients.
KNOCOUT PE Registry Prospective Cohort: 3-Month Data
KNOCOUT PE registry represents the single largest prospective data set in interventional PE treatment to-date, adding evidence to the already most studied device in the PE space. The registry included a wide range of patients with intermediate-high and high-risk PE, showing that contemporary clinical practices are moving to low-dose, shorter duration OPTALYSE protocols and with it comes the benefit of both sustained efficacy and an improved safety profile.
Hi-PEITHO Trial: Patient enrollment gets underway
The largest randomised controlled trial on Intervention vs Anticoagulation in Pulmonary Embolism.
We are pleased to see the official start to the HI-PEITHO trial with the first patient enrollment. HI-PEITHO is the largest, most rigorous trial in the PE space intended to address critical gaps in PE clinical evidence. This trial reflects Boston Scientific’s investment and commitment to providing the highest level of scientific evidence to ultimately help guide clinical practice.
-Dr. Michael R. Jaff, BSC
Ekos™ Endovascular System
Higher-risk Pulmonary Embolism Thrombolysis Study
Introducing the Hi-PEITHO randomised controlled trial for the EKOS™ Endovascular System. The study is the first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for the treatment of pulmonary embolism.
Pulmonary Embolism and COVID-19 | How to handle this new paradigm?